8-K: Ovid Therapeutics Advances Pipeline, Secures Capital

Ovid Therapeutics reports Q2 2025 financial results, advances its neuroscience pipeline, and secures $7.0 million from ganaxolone royalty monetization, while addressing Nasdaq listing compliance.

Summary

• Ovid Therapeutics reported a net loss of $4.7 million, or $0.06 per share, for the second quarter ended June 30, 2025, compared to a net income of $8.5 million, or $0.12 per share, for the same period in 2024.
• Revenue from royalty agreements significantly increased to $6.3 million in Q2 2025 from $169,000 in Q2 2024.
• Research and development expenses decreased to $6.5 million in Q2 2025 from $12.6 million in Q2 2024, primarily due to organizational restructuring.
• General and administrative expenses also decreased to $4.9 million in Q2 2025 from $8.1 million in Q2 2024 due to cost-reduction efforts.
• The company's cash, cash equivalents, and marketable securities totaled $38.3 million as of June 30, 2025, expected to fund operations into early second half 2026.
• Ovid received approval to transfer its common stock to the Nasdaq Capital Market, granting an additional 180-day period until February 9, 2026, to regain compliance with the minimum $1.00 bid price requirement.
• Topline results from the OV329 Phase 1 safety, tolerability, and biomarker study are anticipated in Q3 2025, with a potential Phase 2a trial in drug-resistant epilepsies planned for Q1 2026.
• Safety, tolerability, and pharmacokinetic data for OV350, an intravenous KCC2 direct activator, are expected in Q4 2025.
• IND-enabling activities are underway for OV4071, the first oral KCC2 direct activator, with a proof-of-concept clinical study planned for early 2026 (Q2 2026) for indications like psychosis in Parkinson's disease and Lewy body dementia.
• Ovid monetized its worldwide ganaxolone royalty rights and licensing for $7.0 million in June 2025, strengthening its balance sheet and extending its operational runway.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive. While the company reported a net loss and faces ongoing Nasdaq compliance issues, significant progress in the clinical pipeline, extended cash runway through royalty monetization, and substantial reductions in operating expenses provide a positive outlook on the company's strategic execution and future potential.

Positives

• Successful monetization of ganaxolone royalty rights for $7.0 million, strengthening the balance sheet and extending the operational runway into early 2H 2026.
• Significant reduction in operating expenses, with R&D decreasing by 48.5% and G&A by 39.7% year-over-year due to organizational restructuring and cost-reduction efforts.
• Advancement of the OV329 pipeline with Phase 1 topline results expected in Q3 2025 and plans for a Phase 2a trial in Q1 2026, indicating progress in a potential best-in-class treatment for neuronal excitation.
• Progress in the KCC2 program, including anticipated data for OV350 in Q4 2025 and planned initiation of a proof-of-concept study for the oral KCC2 activator OV4071 in Q2 2026, targeting significant unmet needs in neurological and neuropsychiatric conditions.
• Approval to transfer to the Nasdaq Capital Market provides an additional 180-day period to regain compliance, avoiding immediate delisting.

Negatives

• Reported a net loss of $4.7 million in Q2 2025, a decline from a net income of $8.5 million in Q2 2024, primarily due to a significant reduction in other income.
• The company's common stock has not regained compliance with Nasdaq's minimum bid price requirement of $1.00 per share, necessitating a transfer to the Nasdaq Capital Market.
• Cash, cash equivalents, and marketable securities decreased to $38.3 million as of June 30, 2025, from $53.1 million at December 31, 2024.

Risks

• Failure to regain compliance with Nasdaq's minimum bid price requirement by February 9, 2026, could lead to delisting of the company's common stock.
• There is no assurance that any appeal to a Nasdaq Hearings Panel would be successful or that the company would be able to evidence compliance with any granted extension.
• Uncertainties inherent in the preclinical and clinical development and regulatory approval processes for pipeline candidates (OV329, OV350, OV4071).
• Risks related to the company's ability to achieve its financial objectives and realize the intended benefits of its business strategy.
• Inability to identify suitable business development targets or strategic partners, or to enter into strategic transactions on favorable terms.
• Unanticipated or greater than anticipated impacts or delays due to macroeconomic and geopolitical conditions.

Future Outlook

The company anticipates several key pipeline milestones, including topline results for the OV329 Phase 1 study in Q3 2025, potential initiation of a Phase 2a patient study for OV329 in Q1 2026, results from the OV350 Phase 1 study in Q4 2025, and potential initiation of a proof-of-concept trial for the oral KCC2 direct activator OV4071 in Q2 2026. The current cash, cash equivalents, and marketable securities of $38.3 million are expected to support planned operations and development programs into early second half 2026. The company will continue to explore strategic options like partnerships, co-development, and monetization of assets to accelerate development and offset costs.

Management Comments

• "Our pipeline continues to advance across multiple fronts, with several key readouts anticipated in the near and mid-term. We are on track to share Phase 1 safety, tolerability, and biomarker data for OV329, a potential best-in-class medicine for conditions driven by excess neuronal excitation, including treatment-resistant seizures and pain."
• "Simultaneously, our KCC2 program is advancing well. We expect to read out safety and tolerability data for OV350, our first-in-human KCC2 direct activator, before the end of the year, setting the stage for our broader pipeline of oral KCC2 direct activators."
• "We are also completing IND-enabling work for OV4071 and plan to initiate a Phase 1/1b healthy volunteer and patient study in early 2026. Collectively, these milestones may provide compelling de-risking evidence for drugging and directly activating a new target in the brain with substantial therapeutic opportunity."

Industry Context

Ovid Therapeutics operates in the biopharmaceutical sector, specifically focusing on small molecule medicines for brain conditions characterized by significant unmet medical needs. The company's strategy involves developing novel targeted small molecule candidates that modulate neuronal hyperexcitability, a common factor in various neurological and neuropsychiatric disorders. By advancing first-in-class programs like the KCC2 direct activators, Ovid aims to de-risk new therapeutic targets in the brain, potentially offering differentiated, mechanism-based approaches to conditions like drug-resistant epilepsies and psychosis. The focus on oral formulations for KCC2 activators (OV4071) also aligns with industry trends towards more convenient and patient-friendly drug delivery methods.

Comparison to Industry Standards

• NA

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for increased value from pipeline advancements and extended cash runway, but also face risk of delisting if Nasdaq compliance is not regained. The net loss impacts per-share earnings.
• Employees: The prior organizational restructuring led to reduced operating expenses, implying past workforce adjustments, but the current focus is on advancing the pipeline.
• Patients: Potential for new therapeutic options for brain conditions with high unmet needs if pipeline candidates (OV329, KCC2 activators) successfully advance through clinical trials.
• Creditors: Strengthened balance sheet and extended cash runway improve the company's financial stability and ability to meet short-term obligations.

Next Steps

• Monitor the closing bid price for common stock and explore options, including a reverse stock split, to regain Nasdaq compliance by February 9, 2026.
• Anticipate topline results from the OV329 Phase 1 study in Q3 2025.
• Anticipate safety, tolerability, and pharmacokinetic data for OV350 in Q4 2025.
• Potentially initiate a Phase 2a trial for OV329 in adults with treatment-resistant focal onset seizures in Q1 2026.
• Potentially initiate a proof-of-concept clinical study for OV4071 in Q2 2026.
• Continue to explore strategic options such as partnerships, co-development, regional opportunities, and monetization of equity positions or intellectual property to accelerate development and offset costs.

Key Dates

Recommendation

Ovid Therapeutics is making tangible progress in its clinical pipeline with multiple key readouts and study initiations anticipated in the near term, which could be significant value drivers. The recent $7.0 million royalty monetization has strengthened the balance sheet and extended the cash runway into early 2H 2026, providing financial stability for ongoing operations. However, the persistent Nasdaq minimum bid price non-compliance, despite the transfer to the Nasdaq Capital Market, remains a material risk that could lead to delisting if not resolved by February 2026. While the Q2 2025 net loss of $4.7 million is a negative compared to the prior year's net income, it is largely attributable to the absence of a significant "other income" item present in Q2 2024, rather than a deterioration in core operational efficiency, as evidenced by reduced R&D and G&A expenses. Given the promising pipeline developments balanced against the ongoing listing uncertainty and the shift to a net loss, a "Hold" recommendation is appropriate. Investors should monitor the upcoming clinical data and the company's progress in regaining Nasdaq compliance.

Keywords

Ovid Therapeutics, OVID, biopharmaceutical, neuroscience, brain conditions, OV329, GABA-AT inhibitor, KCC2 activator, OV350, OV4071, drug-resistant epilepsy, psychosis, Parkinson's disease, Lewy body dementia, Nasdaq, delisting, financial results, Q2 2025, royalty monetization, ganaxolone